We have a very high response rate, very deep response rate, and very high MRD negativity rates,” said study presenter Marc S. Raab, MD.

Since its approval, there have been no cases of torsades de pointes or unexplained sudden death among US patients treated with Caprelsa.

Pembrolizumab plus platinum-based chemotherapy has demonstrated efficacy as first-line treatment for advanced penile cancer in a phase 2 trial. The results were published in JAMA Oncology.

Taken together with previous observational, genomic, and early trial data, our findings support the integration of aspirin into clinical practice for a molecularly defined subgroup of patients with ...

Improvements in cause-specific and overall survival seen for those residing in rural and high-poverty communities.

Emerging therapies such as bezuclastinib and elenestinib show promise in improving disease control with potentially fewer toxicities. Other novel strategies, such as immune-based therapies, are under ...

The phase 3 NRG Oncology GU005 trial of SBRT vs MH-IMRT for intermediate-risk prostate cancer had co-primary endpoints including disease control and patient-reported outcomes.

Patients younger than 50 years diagnosed with EOCRC were more likely to have a benign colon indication, bleeding, and family history of CRC.

An investigator presented results from a pre-specified primary efficacy analysis of the phase 2 EXTEND trial testing the progression-free survival (PFS) benefits of metastasis-directed therapy by ...

Effective coordination among multidisciplinary team and individualized management strategies has emerged as a cornerstone of optimal NET care.

Researchers sought to determine whether zanubrutinib would outperform acalabrutinib in an indirect treatment comparison in R/R CLL.